Anastasia V. Popova

Anastasia V. Popova

Auto-generated profile, based on publicly available information

Anastasia V. Popova

National Medical Research Center for Hematology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2025 in Oncohematology
Verified
Journal Article
Open access
PDF file
APA. V. Popova
A. V. Popova
AAA. V. Abakumova
A. V. Abakumova
NAN. K. Arutyunyan
N. K. Arutyunyan
MSMaiia Soloveva
Maiia Soloveva
ASA. A. Startsev
A. A. Startsev
LML. P. Mendeleeva
L. P. Mendeleeva
Background. POEMS‑syndrome is a rare lymphoproliferative disease accompanied by progressive polyneuropathy, which is the leading cause of deterioration in the quality of life and death of patients. Inclusion of autologous hematopoietic stem cell transplantation (auto‑HSCT) into the program therapy in somatically safe young patients is considered in order to achieve long and deep hematologic response and prevent disability. In the published literature, there are no data from large studies on the efficacy of auto‑HSCT in the therapy of such patients. Results of long‑term observations in patients who received auto‑HSCT as a consolidation phase of therapy provide an improved understanding of the efficacy of including high‑dose chemotherapy into program treatment. Aim. To evaluate the efficacy of auto‑HSCT in the program therapy of patients with pOEMS‑syndrome. Materials and methods. The medical records of 687 patients with plasma cell tumors over a 22‑year period (from 2001 to 2023) were retrospectively analyzed. A retrospective, single‑center study included 4 patients with pOEMS‑syndrome who received auto‑HSCT. Results. After induction therapy, partial hematologic response (pR) has been achieved in 100 % of cases. According to vascular endothelial growth factor monitoring 2 patients showed pR, and 1 – complete response (CR). In 100 %of cases, there was a decrease in limb weakness, an increase in the mobility. On the 100th day of auto‑HSCT hematologic response was deepened to CR in 2 cases, 2 patients retained pR, at long‑term follow‑up – 3 CR and 1 pR. vascular endothelial growth factor response: 2 CR, 1 pR, in 1 case – an increase in marker concentration by 17.5 g / L from the upper limit of normal. On the 100th day of auto‑HSCT and at long‑term follow‑up (median 25.5 months) all patients showed further improvement of neurologic status on objective examination and electroneuromyography. Conclusion. Auto‑HSCT provides high frequency of hematologic response, significantly improvement neurologic status and restoration of patients’ working capacity at long‑term follow‑up. The results of clinical studies, literature data, as well as the results of own observations confirm the efficacy of auto‑HSCT when this method is included into the program therapy of somatically safe young patients with pOEMS‑syndrome.

10 December 2025 in Oncohematology
Verified
Journal Article
Open access
PDF file
MSMaiia Soloveva
Maiia Soloveva
IYIgot A Yakutik
Igot A Yakutik
BBBella Biderman
Bella Biderman
APAnastasia V. Popova
Anastasia V. Popova
NRNatalya Risinskaya
Natalya Risinskaya
LMLarisa P. Mendeleeva
Larisa P. Mendeleeva
Background. Multiple myeloma (MM) is a genetically complex disease in which different aberrations can be determined in tumors of different localizations. The impact of mutations in the RAS-ERK pathway genes on the MM course, despite numerous publications, is unclear. Aim. To evaluate mutations in the KRAS, NRAS, BRAF genes in plasma free circulating tumor DNA and CD138+ bone marrow cells and to analyze therapy results of MM patients at different stages depending on MAP kinase genes mutational status. Materials and methods. A prospective single-center study from September 2021 to December 2024 included 100 patients (45 men and 55 women) with newly diagnosed MM aged 29 to 83 years (median 55 years), 41 patients without plasmacytomas and 59 with plasmacytomas. The diagnosis was established in accordance with International Myeloma Working Group – 2014 criteria. Induction therapy was performed according to bortezomib-containing programs; the antitumor response was assessed according to International Myeloma Working Group – 2016 criteria. Analysis of KRAS, NRAS, BRAF genes mutations on DNA samples of CD138+ bone marrow cells was performed in all patients, in free circulating tumor DNA – in 81 patients. Statistical analysis was performed using the MedCalc program, and the Fisher criterion was also used. Survival analysis was performed using the Kaplan–Meier method, with statistical significance assessed using the log-rank test. Results. The frequency of KRAS, NRAS, BRAF genes mutations in free circulating tumor DNA and / or bone marrow in the total group was 50 %. The detection frequency of MAP kinase genes mutations in patients with and without plasmacytomas was comparable. No differences in detection frequency of high-risk cytogenetic aberrations were found in groups of patients with RAS-ERK pathway genes mutations and without them. A tendency towards a lower frequency of achieving complete remission after induction therapy was noted in patients with mutated gene status compared to patients without MAP kinase genes mutations (17 % versus 41 %; p = 0.07). At control time points after auto-transplantation, the trend remained: patients with MAP kinase genes mutations achieved a deep antitumor response 2 times less often compared to patients without mutations (30 % versus 59.5 %; p = 0.051). The probability of two-year progression-free survival of patients with MAP kinase genes mutations was significantly lower (p 0.05) – 62 % versus 92 % for patients without KRAS, NRAS, BRAF genes mutations. Conclusion. Due to the complex genetic structure and spatial anatomical heterogeneity of MM, the study of various localization tumors is extremely relevant. When mutations in the MAP kinase genes are detected, the antitumor response at various therapy stages is worse, and the probability of progression-free survival is significantly lower than in patients without mutations in these genes.

10 December 2025 in Oncohematology
Verified
Journal Article
Open access
PDF file
APAnastasia V. Popova
Anastasia V. Popova
NAN. K. Arutyunyan
N. K. Arutyunyan
MSMaiia Soloveva
Maiia Soloveva
IRI. G. Rekhtina
I. G. Rekhtina
LMLarisa P. Mendeleeva
Larisa P. Mendeleeva
Background. Kidney dysfunction is a common manifestation of multiple myeloma (MM). Kidney damage in MM is most often associated with cast nephropathy; however, rarer forms such as light chain deposition disease (LCDD) and C3 glomerulopathy (C3 GP) also occur. According to several studies, patients with these forms of kidney damage more frequently develop end-stage renal disease and have a worse prognosis for kidney function recovery. Aim. To evaluate the efficacy of induction therapy with targeted drugs followed by consolidation with high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with MM and nephropathy associated with LCDD and C3 GP. Materials and methods. Medical data from 3 patients with MM and nephropathy caused by LCDD (2 cases) and C3 GP (1 case) who received induction therapy followed by auto-HSCT were retrospectively analyzed. Results. At disease onset, impaired kidney function with reduced glomerular filtration rate was detected in all 3 patients; 1 case presented with anuria. All patients received renal replacement therapy. After induction, complete hematologic response was achieved in 2 patients and very good partial response in 1 patient with MM and C3 GP. Renal replacement therapy was discontinued in 2 out of 3 cases. On the 100th day after auto-HSCT, hematologic complete response persisted in 2 patients with LCDD; in the C3 GP case, the response deepened to stringent complete response. All patients achieved renal response, with no need for renal replacement therapy. During long-term follow-up (23–82 months), 1 patient maintained the achieved response, while 2 patients relapsed at 2.5 and 2 years post-auto-HSCT, respectively. Conclusion. Multiple myeloma patients with LCDD- or C3 GP-associated nephropathy exhibit severe kidney dysfunction, often requiring renal replacement therapy, necessitating thorough evaluation in the absence of typical cast nephropathy features. Comprehensive therapy including auto-HSCT in young, fit MM patients with LCDD- or C3 GP-associated nephropathy enables deep hematologic response and improves renal function.